 | • レポートコード：MRC309Z7874 • 出版社/出版日：GlobalInfoResearch / 2023年9月 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界のハーセプチン（トラスツズマブ）&バイオシミラーの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界のハーセプチン（トラスツズマブ）&バイオシミラー市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - ハーセプチン（トラスツズマブ）&バイオシミラーの成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため ハーセプチン（トラスツズマブ）&バイオシミラー市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・ブランド、バイオシミラー 用途別セグメント ・乳がん、胃がん 主要な市場プレーヤー ・Roche、Amgen、Pfizer、Organon、Teva、Viatris 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、ハーセプチン（トラスツズマブ）&バイオシミラー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なハーセプチン（トラスツズマブ）&バイオシミラーメーカーの企業概要、2019年～2022年までのハーセプチン（トラスツズマブ）&バイオシミラーの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なハーセプチン（トラスツズマブ）&バイオシミラーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別ハーセプチン（トラスツズマブ）&バイオシミラーの販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までのハーセプチン（トラスツズマブ）&バイオシミラーの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのハーセプチン（トラスツズマブ）&バイオシミラー市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、およびハーセプチン（トラスツズマブ）&バイオシミラーの産業チェーンを掲載しています。 ・第14、15章では、ハーセプチン（トラスツズマブ）&バイオシミラーの販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - ハーセプチン（トラスツズマブ）&バイオシミラーの概要 - 種類別分析（2018年vs2022年vs2029年）：ブランド、バイオシミラー - 用途別分析（2018年vs2022年vs2029年）：乳がん、胃がん - 世界のハーセプチン（トラスツズマブ）&バイオシミラー市場規模・予測 - 世界のハーセプチン（トラスツズマブ）&バイオシミラー生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Roche、Amgen、Pfizer、Organon、Teva、Viatris ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：ブランド、バイオシミラー ・用途別分析2018年-2029年：乳がん、胃がん ・ハーセプチン（トラスツズマブ）&バイオシミラーの北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・ハーセプチン（トラスツズマブ）&バイオシミラーのヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・ハーセプチン（トラスツズマブ）&バイオシミラーのアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・ハーセプチン（トラスツズマブ）&バイオシミラーの南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・ハーセプチン（トラスツズマブ）&バイオシミラーの中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Herceptin (Trastuzumab) and Biosimilar market size was valued at USD 4642.6 million in 2022 and is forecast to a readjusted size of USD 6357.7 million by 2029 with a CAGR of 4.6% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.
This report is a detailed and comprehensive analysis for global Herceptin (Trastuzumab) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Herceptin (Trastuzumab) and Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Herceptin (Trastuzumab) and Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Herceptin (Trastuzumab) and Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Herceptin (Trastuzumab) and Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Herceptin (Trastuzumab) and Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Herceptin (Trastuzumab) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Organon and Teva and etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Herceptin (Trastuzumab) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Brand
Biosimilar
Market segment by Application
Breast Cancer
Stomach Cancer
Major players covered
Roche
Amgen
Pfizer
Organon
Teva
Viatris
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Herceptin (Trastuzumab) and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Herceptin (Trastuzumab) and Biosimilar, with price, sales, revenue and global market share of Herceptin (Trastuzumab) and Biosimilar from 2018 to 2023.
Chapter 3, the Herceptin (Trastuzumab) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Herceptin (Trastuzumab) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Herceptin (Trastuzumab) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Herceptin (Trastuzumab) and Biosimilar.
Chapter 14 and 15, to describe Herceptin (Trastuzumab) and Biosimilar sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Herceptin (Trastuzumab) and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Brand
1.3.3 Biosimilar
1.4 Market Analysis by Application
1.4.1 Overview: Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Breast Cancer
1.4.3 Stomach Cancer
1.5 Global Herceptin (Trastuzumab) and Biosimilar Market Size & Forecast
1.5.1 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Herceptin (Trastuzumab) and Biosimilar Product and Services
2.1.4 Roche Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Roche Recent Developments/Updates
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Herceptin (Trastuzumab) and Biosimilar Product and Services
2.2.4 Amgen Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Herceptin (Trastuzumab) and Biosimilar Product and Services
2.3.4 Pfizer Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments/Updates
2.4 Organon
2.4.1 Organon Details
2.4.2 Organon Major Business
2.4.3 Organon Herceptin (Trastuzumab) and Biosimilar Product and Services
2.4.4 Organon Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Organon Recent Developments/Updates
2.5 Teva
2.5.1 Teva Details
2.5.2 Teva Major Business
2.5.3 Teva Herceptin (Trastuzumab) and Biosimilar Product and Services
2.5.4 Teva Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Teva Recent Developments/Updates
2.6 Viatris
2.6.1 Viatris Details
2.6.2 Viatris Major Business
2.6.3 Viatris Herceptin (Trastuzumab) and Biosimilar Product and Services
2.6.4 Viatris Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Viatris Recent Developments/Updates
3 Competitive Environment: Herceptin (Trastuzumab) and Biosimilar by Manufacturer
3.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Herceptin (Trastuzumab) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Herceptin (Trastuzumab) and Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Herceptin (Trastuzumab) and Biosimilar Manufacturer Market Share in 2022
3.5 Herceptin (Trastuzumab) and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Herceptin (Trastuzumab) and Biosimilar Market: Region Footprint
3.5.2 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Type Footprint
3.5.3 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Herceptin (Trastuzumab) and Biosimilar Market Size by Region
4.1.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2018-2029)
4.2 North America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.3 Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.5 South America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2029)
7 North America
7.1 North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Herceptin (Trastuzumab) and Biosimilar Market Size by Country
7.3.1 North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Herceptin (Trastuzumab) and Biosimilar Market Size by Country
8.3.1 Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Herceptin (Trastuzumab) and Biosimilar Market Size by Country
10.3.1 South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Herceptin (Trastuzumab) and Biosimilar Market Drivers
12.2 Herceptin (Trastuzumab) and Biosimilar Market Restraints
12.3 Herceptin (Trastuzumab) and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Herceptin (Trastuzumab) and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Herceptin (Trastuzumab) and Biosimilar
13.3 Herceptin (Trastuzumab) and Biosimilar Production Process
13.4 Herceptin (Trastuzumab) and Biosimilar Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Herceptin (Trastuzumab) and Biosimilar Typical Distributors
14.3 Herceptin (Trastuzumab) and Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer